Page 2 - Aadi Bioscience News Today

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.

Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) Chairman Neil Desai sold 42,000 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $1.74, for a total value of $73,080.00. Following the completion of the sale, the chairman now owns 1,453,543 shares […]

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...

/PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients...

Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) was the recipient of a large growth in short interest in November. As of November 30th, there was short interest totalling 789,000 shares, a growth of 6.1% from the November 15th total of 743,700 shares. Currently, 4.6% of the company’s stock are sold short. Based on an […]

-- Price: 2.32, Change: -3.05, Percent Change: -56.80 ...

-- Price: 2.78, Change: -2.59, Percent Change: -48.23 ...

Friday, Aadi Bioscience Inc (NASDAQ: AADI) released results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial of nab-sirolimus in patients with 

Interim results from investigator-assessed responses in first 40 patients from TSC1 and TSC2 arms demonstrate sustained tumor reductions in heavily pre-treated population 80 patients now enrolled...